
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/861331/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Effect of Exclusion Diets on Symptom Severity and the Gut Microbiota in Patients With Irritable Bowel Syndrome. Clinical Gastroenterology and Hepatology, 2022, 20, e465-e483.	2.4	20
2	The Transition From Rome III to Rome IV Irritable Bowel Syndrome: What We Gain and Lose. Clinical Gastroenterology and Hepatology, 2022, 20, 508-510.	2.4	6
3	Gender and Other Factors Associated with Endoscopy Volume Among U.S. Gastroenterology Fellows. Clinical Gastroenterology and Hepatology, 2022, 20, 2911-2914.e4.	2.4	1
4	Obesity is associated with a distinct brain-gut microbiome signature that connects Prevotella and Bacteroides to the brain's reward center. Gut Microbes, 2022, 14, 2051999.	4.3	28
5	AGA Clinical Practice Update on the Role of Diet in Irritable Bowel Syndrome: Expert Review. Gastroenterology, 2022, 162, 1737-1745.e5.	0.6	38
6	Reply. Clinical Gastroenterology and Hepatology, 2022, , .	2.4	0
7	The visceral sensitivity index: A novel tool for measuring Glâ€symptomâ€specific anxiety in inflammatory bowel disease. Neurogastroenterology and Motility, 2022, 34, e14384.	1.6	4
8	Risk Factors for Abdominal Pain–Related Disorders of Gut–Brain Interaction in Adults and Children: A Systematic Review. Gastroenterology, 2022, 163, 995-1023.e3.	0.6	28
9	AGA Clinical Practice Guideline on the Pharmacological Management of Irritable Bowel Syndrome With Diarrhea. Gastroenterology, 2022, 163, 137-151.	0.6	43
10	AGA Clinical Practice Guideline on the Pharmacological Management of Irritable Bowel Syndrome With Constipation. Gastroenterology, 2022, 163, 118-136.	0.6	45
11	Wearable Devices Are Well Accepted by Patients in the Study and Management of Inflammatory Bowel Disease: A Survey Study. Digestive Diseases and Sciences, 2021, 66, 1836-1844.	1.1	14
12	Cytokine Levels and Symptoms Among Women with Irritable Bowel Syndrome: Considering the Role of Hormonal Contraceptive Use. Biological Research for Nursing, 2021, 23, 171-179.	1.0	6
13	Price Is Right: Exploring Prescription Drug Coverage Barriers for Irritable Bowel Syndrome Using Threshold Pricing Analysis. Digestive Diseases and Sciences, 2021, 66, 4140-4148.	1.1	4
14	Unconscious Bias in Peer Review. Clinical Gastroenterology and Hepatology, 2021, 19, 419-420.	2.4	13
15	Tegaserod for Irritable Bowel Syndrome With Constipation in Women Younger Than 65 Years Without Cardiovascular Disease: Pooled Analyses of 4 Controlled Trials. American Journal of Gastroenterology, 2021, 116, 1601-1611.	0.2	15
16	ls It Time to Abandon Gastric Emptying in Patients With Symptoms of Gastroparesis and Functional Dyspepsia?. Clinical Gastroenterology and Hepatology, 2021, , .	2.4	1
17	A survey of gastroenterologists in the United States on the use of central neuromodulators for treating irritable bowel syndrome. Alimentary Pharmacology and Therapeutics, 2021, 54, 281-291.	1.9	8
18	The Colonic Mucosal MicroRNAs, MicroRNA-219a-5p, and MicroRNA-338-3p Are Downregulated in Irritable Bowel Syndrome and Are Associated With Barrier Function and MAPK Signaling. Gastroenterology, 2021, 160, 2409-2422.e19.	0.6	26

#	Article	IF	CITATIONS
19	Reply. Clinical Gastroenterology and Hepatology, 2021, , .	2.4	Ο
20	Efficacy of Linaclotide in Reducing Abdominal Symptoms of Bloating, Discomfort, and Pain: A Phase 3B Trial Using a Novel Abdominal Scoring System. American Journal of Gastroenterology, 2021, 116, 1929-1937.	0.2	19
21	A Review of the Evidence and Recommendations on Communication Skills and the Patient–Provider Relationship: AÂRome Foundation Working Team Report. Gastroenterology, 2021, 161, 1670-1688.e7.	0.6	56
22	Latest Insights on the Pathogenesis of Irritable Bowel Syndrome. Gastroenterology Clinics of North America, 2021, 50, 505-522.	1.0	14
23	Small intestinal immunopathology and GI-associated antibody formation in hereditary alpha-tryptasemia. Journal of Allergy and Clinical Immunology, 2021, 148, 813-821.e7.	1.5	17
24	How to Approach a Patient with Difficult-to-Treat IBS. Gastroenterology, 2021, 161, 1092-1098.e3.	0.6	6
25	Contrasting Clinician and Insurer Perspectives to Managing Irritable Bowel Syndrome: Multilevel Modeling Analysis. American Journal of Gastroenterology, 2021, 116, 748-757.	0.2	18
26	Increasing Rates of Opioid Prescriptions for Gastrointestinal Diseases in the United States. American Journal of Gastroenterology, 2021, 116, 796-807.	0.2	11
27	High Opioid Prescribing Profiles Among Gastroenterologists: A Nationwide Analysis. Clinical Gastroenterology and Hepatology, 2021, , .	2.4	3
28	Longitudinal Autonomic Nervous System Measures Correlate With Stress and Ulcerative Colitis Disease Activity and Predict Flare. Inflammatory Bowel Diseases, 2021, 27, 1576-1584.	0.9	22
29	Genome-wide analysis of 53,400 people with irritable bowel syndrome highlights shared genetic pathways with mood and anxiety disorders. Nature Genetics, 2021, 53, 1543-1552.	9.4	96
30	Benefits and Pitfalls of Change From Rome III to Rome IV Criteria for Irritable Bowel Syndrome and Fecal Incontinence. Clinical Gastroenterology and Hepatology, 2020, 18, 297-299.	2.4	9
31	Opioid Prescription Patterns Among US Gastroenterologists From 2013 to 2017. Gastroenterology, 2020, 158, 776-779.e2.	0.6	7
32	Risk and Protective Factors Related to Early Adverse Life Events in Irritable Bowel Syndrome. Journal of Clinical Gastroenterology, 2020, 54, 63-69.	1.1	28
33	The Role of Resilience in Irritable Bowel Syndrome, Other Chronic Gastrointestinal Conditions, and the General Population. Clinical Gastroenterology and Hepatology, 2020, 19, 2541-2550.e1.	2.4	18
34	Analysis of brain networks and fecal metabolites reveals brain–gut alterations in premenopausal females with irritable bowel syndrome. Translational Psychiatry, 2020, 10, 367.	2.4	17
35	Epigenetic Mechanisms in Irritable Bowel Syndrome. Frontiers in Psychiatry, 2020, 11, 805.	1.3	23
36	Postmenopausal women with irritable bowel syndrome (IBS) have more severe symptoms than premenopausal women with IBS. Neurogastroenterology and Motility, 2020, 32, e13913.	1.6	17

#	Article	IF	CITATIONS
37	Importance of traumaâ€related fear in patients with irritable bowel syndrome and early adverse life events. Neurogastroenterology and Motility, 2020, 32, e13896.	1.6	9
38	Pain Phenotypes in Chronic Pancreatitis: Beginning to Fine-tune Our Approach to Treatment. Clinical Gastroenterology and Hepatology, 2020, , .	2.4	0
39	Impact of patient and disease characteristics on the efficacy and safety of eluxadoline for IBS-D: a subgroup analysis of phase III trials. Therapeutic Advances in Gastroenterology, 2019, 12, 175628481984129.	1.4	12
40	µâ€opioid receptor, βâ€endorphin, and cannabinoid receptorâ€2 are increased in the colonic mucosa of irritable bowel syndrome patients. Neurogastroenterology and Motility, 2019, 31, e13688.	1.6	25
41	miR-24 Is Elevated in Ulcerative Colitis Patients and Regulates Intestinal Epithelial Barrier Function. American Journal of Pathology, 2019, 189, 1763-1774.	1.9	31
42	Negative Events During Adulthood Are Associated With Symptom Severity and Altered Stress Response in Patients With Irritable Bowel Syndrome. Clinical Gastroenterology and Hepatology, 2019, 17, 2245-2252.	2.4	21
43	Plasma Corticotropin-Releasing Factor Receptors and B7-2+ Extracellular Vesicles in Blood Correlate with Irritable Bowel Syndrome Disease Severity. Cells, 2019, 8, 101.	1.8	12
44	487 Use of Central Neuromodulators by Gastroenterologists in the Treatment of IBS: A Pilot Survey. American Journal of Gastroenterology, 2019, 114, S282-S282.	0.2	0
45	489 Opioid and Neuromodulator Prescription Patterns Among U.S. Gastroenterologists. American Journal of Gastroenterology, 2019, 114, S283-S283.	0.2	Ο
46	The Gut Microbiome and Digestive Health – A New Frontier. Clinical Gastroenterology and Hepatology, 2019, 17, 215-217.	2.4	7
47	Predictors of Health-related Quality of Life in Irritable Bowel Syndrome Patients Compared With Healthy Individuals. Journal of Clinical Gastroenterology, 2019, 53, e142-e149.	1.1	27
48	Activation of pruritogenic TGR5, MrgprA3, and MrgprC11 on colon-innervating afferents induces visceral hypersensitivity. JCI Insight, 2019, 4, .	2.3	59
49	Increased Prevalence of Rare Sucrase-isomaltase PathogenicÂVariants in Irritable Bowel Syndrome Patients. Clinical Gastroenterology and Hepatology, 2018, 16, 1673-1676.	2.4	64
50	Functional Bowel Disorders. Gastroenterology, 2018, 155, 1-4.	0.6	16
51	Functional Bowel Disorders: A Roadmap to Guide the Next Generation of Research. Gastroenterology, 2018, 154, 723-735.	0.6	55
52	Using the Rome IV Criteria to Help Manage the Complex IBS Patient. American Journal of Gastroenterology, 2018, 113, 453-456.	0.2	11
53	Female-Specific Association Between Variants on Chromosome 9 and Self-Reported Diagnosis of Irritable Bowel Syndrome. Gastroenterology, 2018, 155, 168-179.	0.6	55
54	Functional variants in the sucrase–isomaltase gene associate with increased risk of irritable bowel syndrome. Gut, 2018, 67, 263-270.	6.1	120

#	Article	IF	CITATIONS
55	Resilience is decreased in irritable bowel syndrome and associated with symptoms and cortisol response. Neurogastroenterology and Motility, 2018, 30, e13155.	1.6	39
56	Irritable bowel syndrome patients have <i>SCN5A</i> channelopathies that lead to decreased Na _V 1.5 current and mechanosensitivity. American Journal of Physiology - Renal Physiology, 2018, 314, G494-G503.	1.6	40
57	Sigmoid colon mucosal gene expression supports alterations of neuronal signaling in irritable bowel syndrome with constipation. American Journal of Physiology - Renal Physiology, 2018, 315, G140-G157.	1.6	18
58	1090 - Epigenetic Changes in Blood Cells and Colonic Mucosa are Associated with Irritable Bowel Syndrome (IBS). Gastroenterology, 2018, 154, S-214.	0.6	4
59	The Long Non-Coding RNA AFDN-AS1 Is Expressed in Colonic Epithelial Cells. American Journal of Gastroenterology, 2018, 113, S262-S263.	0.2	0
60	Comparison of Symptoms, Healthcare Utilization, and Treatment in Diagnosed and Undiagnosed Individuals With Diarrhea-Predominant Irritable Bowel Syndrome. American Journal of Gastroenterology, 2017, 112, 892-899.	0.2	47
61	Early adverse life events are associated with altered brain network architecture in a sex- dependent manner. Neurobiology of Stress, 2017, 7, 16-26.	1.9	43
62	Responsiveness to Change and Minimally Important Differences of the Patient-Reported Outcomes Measurement Information System Gastrointestinal Symptoms Scales. Digestive Diseases and Sciences, 2017, 62, 1186-1192.	1.1	36
63	Sex-Related Differences in GI Disorders. Handbook of Experimental Pharmacology, 2017, 239, 177-192.	0.9	23
64	Gene expression profiles in peripheral blood mononuclear cells correlate with salience network activity in chronic visceral pain: A pilot study. Neurogastroenterology and Motility, 2017, 29, e13027.	1.6	18
65	Increased Sleep Disturbances in Irritable Bowel Syndrome (IBS) Patients is Associated with Greater Symptom Severity and Decreased Quality Of Life. Gastroenterology, 2017, 152, S716.	0.6	3
66	Colonic Mucosal Microbiome is Associated with Mucosal Microrna Expression in Irritable Bowel Syndrome. Gastroenterology, 2017, 152, S40-S41.	0.6	1
67	Dysregulation of the Long-Noncoding RNA, Ghrlos, in Irritable Bowel Syndrome. Gastroenterology, 2017, 152, S722.	0.6	3
68	Morphological brain measures of corticoâ€limbic inhibition related to resilience. Journal of Neuroscience Research, 2017, 95, 1760-1775.	1.3	38
69	Gastrointestinal symptom severity in irritable bowel syndrome, inflammatory bowel disease and the general population. Neurogastroenterology and Motility, 2017, 29, e13003.	1.6	21
70	Repeat treatment with rifaximin improves irritable bowel syndrome-related quality of life: a secondary analysis of a randomized, double-blind, placebo-controlled trial. Therapeutic Advances in Gastroenterology, 2017, 10, 689-699.	1.4	18
71	Expression Profiling of Sigmoid Biopsies in Irritable Bowel Syndrome vs Healthy Controls. Gastroenterology, 2017, 152, S722.	0.6	1
72	Trauma Severity and Lack of Confiding in Others Increases Risk of Having Irritable Bowel Syndrome. Gastroenterology, 2017, 152, S711-S712.	0.6	0

#	Article	IF	CITATIONS
73	Resilience is Associated with Early Life Stress and HPA Axis Response in IBS. Gastroenterology, 2017, 152, S921.	0.6	0
74	Sex-Dependent Alterations of Colonic Epithelial Permeability in Irritable Bowel Syndrome. Gastroenterology, 2017, 152, S723.	0.6	0
75	Impact of Rifaximin on Health-Related Quality of Life in Patients with Diarrhea-Predominant Irritable Bowel Syndrome. Gastroenterology, 2017, 152, S913.	0.6	Ο
76	Predictors of Quality of Life in Irritable Bowel Syndrome Compared to Healthy Controls. Gastroenterology, 2017, 152, S714-S715.	0.6	0
77	Systemic sclerosis is associated with specific alterations in gastrointestinal microbiota in two independent cohorts. BMJ Open Gastroenterology, 2017, 4, e000134.	1.1	77
78	Chronic constipation. Nature Reviews Disease Primers, 2017, 3, 17095.	18.1	203
79	Current and emergent pharmacologic treatments for irritable bowel syndrome with diarrhea: evidence-based treatment in practice. Therapeutic Advances in Gastroenterology, 2017, 10, 253-275.	1.4	36
80	Impact of Baseline Pain Severity on the Efficacy of Eluxadoline in Patients with Irritable Bowel Syndrome with Diarrhea. American Journal of Gastroenterology, 2016, 111, S254.	0.2	1
81	Evaluation of the Patient Reported Outcomes Measurement Information System (PROMIS) in Celiac Disease. American Journal of Gastroenterology, 2016, 111, S464.	0.2	Ο
82	Expression of the Bitter Taste Receptor, T2R38, in Enteroendocrine Cells of the Colonic Mucosa of Overweight/Obese vs. Lean Subjects. PLoS ONE, 2016, 11, e0147468.	1.1	52
83	Genomeâ€wide <scp>DNA</scp> methylation profiling of peripheral blood mononuclear cells in irritable bowel syndrome. Neurogastroenterology and Motility, 2016, 28, 410-422.	1.6	29
84	2015 James W. Freston Single Topic Conference: A Renaissance in the Understanding and Management of Irritable Bowel Syndrome. Clinical Gastroenterology and Hepatology, 2016, 14, e77-e86.	2.4	3
85	Tu1788 Corticotropin-Releasing Hormone Receptor 1 (CRH-R1) Polymorphisms are Associated With Irritable Bowel Syndrome (IBS) and Acoustic Startle Response (ASR). Gastroenterology, 2016, 150, S946-S947.	0.6	0
86	Tu1794 Functional Pathways Associated With Differential Colonic Mucosal Expression of microRNA and mRNA in Irritable Bowel Syndrome. Gastroenterology, 2016, 150, S949.	0.6	0
87	Mo1616 Resilience Is Decreased in Irritable Bowel Syndrome (IBS) and Associated With Poorer Quality of Life and Greater Symptom Severity. Gastroenterology, 2016, 150, S731.	0.6	4
88	Tu1799 Differences in Cortisol Responses to Hormone Challenge vs. Visceral Stressor in Irritable Bowel Syndrome. Gastroenterology, 2016, 150, S950-S951.	0.6	0
89	Tu1803 IBS-Associated SCN5A Mutation G615E Results in a NaV1.5 Channel With Normal Na+ Current Density but Loss of Mechanosensitivity. Gastroenterology, 2016, 150, S952.	0.6	0
90	The effect of sex and irritable bowel syndrome on HPA axis response and peripheral glucocorticoid receptor expression. Psychoneuroendocrinology, 2016, 69, 67-76.	1.3	43

#	Article	IF	CITATIONS
91	Development and Validation of the Rome IV Diagnostic Questionnaire for Adults. Gastroenterology, 2016, 150, 1481-1491.	0.6	400
92	Bowel Disorders. Gastroenterology, 2016, 150, 1393-1407.e5.	0.6	1,912
93	2015 James W. Freston Single Topic Conference: AÂRenaissanceÂin the Understanding and Management ofÂlrritable Bowel Syndrome. Cellular and Molecular Gastroenterology and Hepatology, 2016, 2, 394-399.e2.	2.3	4
94	Effects of baseline abdominal pain and bloating on response to lubiprostone in patients with irritable bowel syndrome with constipation. Alimentary Pharmacology and Therapeutics, 2016, 44, 1114-1122.	1.9	47
95	Corticotropin-releasing hormone receptor 1 (CRH-R1) polymorphisms are associated with irritable bowel syndrome and acoustic startle response. Psychoneuroendocrinology, 2016, 73, 133-141.	1.3	8
96	Adverse childhood experiences are associated with irritable bowel syndrome and gastrointestinal symptom severity. Neurogastroenterology and Motility, 2016, 28, 1252-1260.	1.6	88
97	366 Guanylate Cyclase-C Expression Is Down-Regulated in Colonic Biopsies From Female Irritable Bowel Syndrome Patients With Constipation. Gastroenterology, 2016, 150, S81-S82.	0.6	2
98	Tu1802 Colonic Immune Cells in Irritable Bowel Syndrome: A Systematic Review and Meta-Analysis. Gastroenterology, 2016, 150, S951-S952.	0.6	0
99	Interactions of early adversity with stress-related gene polymorphisms impact regional brain structure in females. Brain Structure and Function, 2016, 221, 1667-1679.	1.2	26
100	A crossâ€cultural investigation of attachment style, catastrophizing, negative pain beliefs, and symptom severity in irritable bowel syndrome. Neurogastroenterology and Motility, 2015, 27, 490-500.	1.6	13
101	Rifaximin Repeat Treatment in Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D) Produced No Clinically Significant Changes in Stool Microbial Antibiotic Sensitivity. American Journal of Gastroenterology, 2015, 110, S761.	0.2	2
102	MicroRNA214 Is Associated With Progression of Ulcerative Colitis, and Inhibition Reduces Development of Colitis and Colitis-Associated Cancer in Mice. Gastroenterology, 2015, 149, 981-992.e11.	0.6	112
103	313 Effects of Rifaximin on Urgency, Bloating, and Abdominal Pain in Patients With IBS-D: A Randomized, Controlled, Repeat Treatment Study. Gastroenterology, 2015, 148, S-69.	0.6	7
104	Mo1273 The Association of Early Adverse Life Events and Irritable Bowel Syndrome (IBS) Is Amplified by the Presence of Peritraumatic Fear. Gastroenterology, 2015, 148, S-656-S-657.	0.6	1
105	Computer versus physician identification of gastrointestinal alarm features. International Journal of Medical Informatics, 2015, 84, 1111-1117.	1.6	20
106	Diminished Expression of Corticotropin-Releasing Hormone Receptor 2 in Human Colon Cancer Promotes Tumor Growth and Epithelial-to-Mesenchymal Transition via Persistent Interleukin-6/Stat3 Signaling. Cellular and Molecular Gastroenterology and Hepatology, 2015, 1, 610-630.	2.3	36
107	Computer-Generated Vs. Physician-Documented History of Present Illness (HPI): Results of a Blinded Comparison. American Journal of Gastroenterology, 2015, 110, 170-179.	0.2	41
108	Catecholaminergic Gene Polymorphisms Are Associated with GI Symptoms and Morphological Brain Changes in Irritable Bowel Syndrome. PLoS ONE, 2015, 10, e0135910.	1.1	18

#	Article	IF	CITATIONS
109	Effect of Eluxadoline on Abdominal and Bowel Symptoms Over Time in Phase 3 Clinical Trials in Patients With Irritable Bowel Syndrome With Diarrhea. American Journal of Gastroenterology, 2015, 110, S748.	0.2	1
110	Negative Feedback of the Hypothalamic Pituitary Adrenal (HPA) Axis as Assessed by the Dexamethasone-Corticotropin Releasing Factor (CRF) Test in Irritable Bowel Syndrome (IBS). American Journal of Gastroenterology, 2015, 110, S755-S756.	0.2	1
111	MicroRNA targeting for the therapy of colitis-associated colon cancer Journal of Clinical Oncology, 2015, 33, 571-571.	0.8	0
112	The Effect of Sex and Irritable Bowel Syndrome (IBS) on the Integrated Hypothalamic-Pituitary-Adrenal (HPA) Axis Response to Hormone Challenge. American Journal of Gastroenterology, 2015, 110, S757.	0.2	0
113	Development of the NIH Patient-Reported Outcomes Measurement Information System (PROMIS) Gastrointestinal Symptom Scales. American Journal of Gastroenterology, 2014, 109, 1804-1814.	0.2	190
114	The impact of abdominal pain on global measures in patients with chronic idiopathic constipation, before and after treatment with linaclotide: a pooled analysis of two randomised, doubleâ€blind, placeboâ€controlled, phase 3 trials. Alimentary Pharmacology and Therapeutics, 2014, 40, 1302-1312.	1.9	25
115	Construct Validity of the Patientâ€Reported Outcomes Measurement Information System Gastrointestinal Symptom Scales in Systemic Sclerosis. Arthritis Care and Research, 2014, 66, 1725-1730.	1.5	24
116	Safety and tolerability of rifaximin for the treatment of irritable bowel syndrome without constipation: a pooled analysis of randomised, doubleâ€blind, placeboâ€controlled trials. Alimentary Pharmacology and Therapeutics, 2014, 39, 1161-1168.	1.9	90
117	American Gastroenterological Association Institute Technical Review on the Pharmacological Management of Irritable Bowel Syndrome. Gastroenterology, 2014, 147, 1149-1172.e2.	0.6	113
118	GERD Symptoms in the General Population: Prevalence and Severity Versus Care-Seeking Patients. Digestive Diseases and Sciences, 2014, 59, 2488-2496.	1.1	45
119	Development of an Online Library of Patient-Reported Outcome Measures in Gastroenterology: The GI-PRO Database. American Journal of Gastroenterology, 2014, 109, 234-248.	0.2	25
120	Guanylate Cyclase-C Receptor and Ligand Expression in Colonic Mucosa in Chronic Constipation. American Journal of Gastroenterology, 2014, 109, S540.	0.2	2
121	Autonomic response to a visceral stressor is dysregulated in irritable bowel syndrome and correlates with duration of disease. Neurogastroenterology and Motility, 2013, 25, e650-9.	1.6	37
122	A 9-year evaluation of temporal trends in alosetron postmarketing safety under the risk management program. Therapeutic Advances in Gastroenterology, 2013, 6, 344-357.	1.4	47
123	Identification of a Functional TPH1 Polymorphism Associated With Irritable Bowel Syndrome Bowel Habit Subtypes. American Journal of Gastroenterology, 2013, 108, 1766-1774.	0.2	29
124	An Evidence-Based Look at Misconceptions in the Treatment of Patients with IBS-D. Gastroenterology and Hepatology, 2013, 9, 1-24.	0.2	4
125	Gastrointestinal and Psychological Mediators of Health-Related Quality of Life in IBS and IBD: A Structural Equation Modeling Analysis. American Journal of Gastroenterology, 2012, 107, 451-459.	0.2	71
126	Response to Drs Trivedi and Ward. American Journal of Gastroenterology, 2012, 107, 140-141.	0.2	3

#	Article	IF	CITATIONS
127	Association Between Early Adverse Life Events and Irritable Bowel Syndrome. Clinical Gastroenterology and Hepatology, 2012, 10, 385-390.e3.	2.4	251
128	Serum and Colonic Mucosal Immune Markers in Irritable Bowel Syndrome. American Journal of Gastroenterology, 2012, 107, 262-272.	0.2	131
129	Effects of Linaclotide on Abdominal and Bowel Symptoms Over the First Seven Days of Treatment in Patients with Irritable Bowel Syndrome with Constipation. American Journal of Gastroenterology, 2012, 107, S710-S711.	0.2	1
130	9-Year Evaluation of Temporal Trends in Alosetron Postmarketing Safety Under the Risk Management Program. American Journal of Gastroenterology, 2012, 107, S703-S704.	0.2	0
131	Characteristics of Acute Pain Attacks in Patients With Irritable Bowel Syndrome Meeting Rome III Criteria. American Journal of Gastroenterology, 2011, 106, 1299-1307.	0.2	29
132	Understanding the Multidimensional Nature of Illness Severity as Measured by Patient-Reported Outcome Measures in Irritable Bowel Syndrome. Clinical Gastroenterology and Hepatology, 2011, 9, 918-919.	2.4	4
133	Do Patients Understand the Bristol Stool Scale? Results of Cognitive De-Briefing of IBS Patients. Gastroenterology, 2011, 140, S-615.	0.6	4
134	Emerging Pharmacological Therapies for the Irritable Bowel Syndrome. Gastroenterology Clinics of North America, 2011, 40, 223-243.	1.0	16
135	The Role of Stress on Physiologic Responses and Clinical Symptoms in Irritable Bowel Syndrome. Gastroenterology, 2011, 140, 761-765.e5.	0.6	194
136	A Functional Promoter Variant in the Tryptophan Hydroxylase 1 Gene is Associated With a Bowel Habit Phenotype in Patients With Irritable Bowel Syndrome (IBS). Gastroenterology, 2011, 140, S-111.	0.6	0
137	Factors Analysis of Bowel Symptoms in IBS: Guidance for Patient Reported Outcome (PRO) Development. Gastroenterology, 2011, 140, S-605-S-606.	0.6	0
138	Treatment of bloating and distension - role of probiotics: authors' reply. Alimentary Pharmacology and Therapeutics, 2011, 34, 581-583.	1.9	0
139	Understanding Gastrointestinal Distress: A Framework for Clinical Practice. American Journal of Gastroenterology, 2011, 106, 380-385.	0.2	34
140	A Randomized Placebo-Controlled Phase IIb Trial of A3309, A Bile Acid Transporter Inhibitor, for Chronic Idiopathic Constipation. American Journal of Gastroenterology, 2011, 106, 1803-1812.	0.2	156
141	Challenges and prospects for pharmacotherapy in functional gastrointestinal disorders. Therapeutic Advances in Gastroenterology, 2010, 3, 291-305.	1.4	12
142	Diagnosis and management of IBS. Nature Reviews Gastroenterology and Hepatology, 2010, 7, 565-581.	8.2	96
143	Is Irritable Bowel Syndrome a Diagnosis of Exclusion? A Survey of Primary Care Providers, Gastroenterologists, and IBS Experts. American Journal of Gastroenterology, 2010, 105, 848-858.	0.2	153
144	Differences in Gastrointestinal Symptoms According to Gender in Rome II Positive IBS and Dyspepsia in a Latin American Population. American Journal of Gastroenterology, 2010, 105, 925-932.	0.2	36

#	Article	IF	CITATIONS
145	Ischemic Colitis and Complications of Constipation Associated With the Use of Alosetron Under a Risk Management Plan: Clinical Characteristics, Outcomes, and Incidences. American Journal of Gastroenterology, 2010, 105, 866-875.	0.2	77
146	Rome Foundation Endpoints and Outcomes Conference 2009: Optimizing Clinical Trials in FGID. American Journal of Gastroenterology, 2010, 105, 722-730.	0.2	21
147	An Evidence-based Approach to Therapy in IBS-D: A Case Study Compendium. Gastroenterology and Hepatology, 2010, 6, 1-12.	0.2	9
148	Developing Valid and Reliable Health Utilities in Irritable Bowel Syndrome: Results From the IBS PROOF Cohort. American Journal of Gastroenterology, 2009, 104, 1984-1991.	0.2	60
149	A Focus Group Assessment of Patient Perspectives on Irritable Bowel Syndrome and Illness Severity. Digestive Diseases and Sciences, 2009, 54, 1532-1541.	1.1	102
150	Childhood Trauma Is Associated With Hypothalamic-Pituitary-Adrenal Axis Responsiveness in Irritable Bowel Syndrome. Gastroenterology, 2009, 137, 1954-1962.	0.6	167
151	Do fluctuations in ovarian hormones affect gastrointestinal symptoms in women with irritable bowel syndrome?. Gender Medicine, 2009, 6, 152-167.	1.4	116
152	Do Proton Pump Inhibitors (PPIs) Predispose to the Development of SIBO in IBS versus Non-IBS Patients?. American Journal of Gastroenterology, 2009, 104, S103-S104.	0.2	2
153	Is IBS a Predictor of SIBO as Identified by Hydrogen/Methane Breath Testing?. American Journal of Gastroenterology, 2009, 104, S110.	0.2	1
154	Novel techniques to study visceral hypersensitivity in irritable bowel syndrome. Current Gastroenterology Reports, 2008, 10, 369-378.	1.1	13
155	Challenges to the Therapeutic Pipeline for Irritable Bowel Syndrome: End Points and Regulatory Hurdles. Gastroenterology, 2008, 135, 1877-1891.	0.6	65
156	T1026 Measuring IBS Patient Reported Outcomes with a Single Item Numeric Rating Scale: Results from the PROOF Cohort. Gastroenterology, 2008, 134, A-467.	0.6	4
157	Bacterial Overgrowth and Irritable Bowel Syndrome: Unifying Hypothesis or a Spurious Consequence of Proton Pump Inhibitors?. American Journal of Gastroenterology, 2008, 103, 2972-2976.	0.2	91
158	Predictors of Patient-Assessed Illness Severity in Irritable Bowel Syndrome. American Journal of Gastroenterology, 2008, 103, 2536-2543.	0.2	112
159	Functional GI disorders: from animal models to drug development. Gut, 2008, 57, 384-404.	6.1	140
160	New Treatments for Irritable Bowel Syndrome in Women. Women's Health, 2008, 4, 605-622.	0.7	16
161	Increased Acoustic Startle Responses in IBS Patients During Abdominal and Nonabdominal Threat. Psychosomatic Medicine, 2008, 70, 920-927.	1.3	39
162	Alosetron: An Effective Treatment for Diarrhea-Predominant Irritable Bowel Syndrome. Women's Health, 2007, 3, 15-27.	0.7	7

#	Article	IF	CITATIONS
163	The Central Role of Gastrointestinal-Specific Anxiety in Irritable Bowel Syndrome: Further Validation of the Visceral Sensitivity Index. Psychosomatic Medicine, 2007, 69, 89-98.	1.3	196
164	Irritable Bowel Syndrome: Current Approach to Symptoms, Evaluation, and Treatment. Gastroenterology Clinics of North America, 2007, 36, 665-685.	1.0	48
165	Attentional modulation of visceral and somatic pain. Neurogastroenterology and Motility, 2007, 19, 569-577.	1.6	63
166	Gender, Age, Society, Culture, and the Patient's Perspective in the Functional Gastrointestinal Disorders. Gastroenterology, 2006, 130, 1435-1446.	0.6	320
167	Neuroendocrine and Neuroimmune Markers in IBS: Pathophysiological Role or Epiphenomenon?. Gastroenterology, 2006, 130, 596-600.	0.6	22
168	Longitudinal Change in Perceptual and Brain Activation Response to Visceral Stimuli in Irritable Bowel Syndrome Patients. Gastroenterology, 2006, 131, 352-365.	0.6	175
169	Irritable bowel syndrome: new and emerging therapies. Current Opinion in Internal Medicine, 2006, 5, 297-304.	1.5	7
170	Effect of sex on perception of rectosigmoid stimuli in irritable bowel syndrome. American Journal of Physiology - Regulatory Integrative and Comparative Physiology, 2006, 291, R277-R284.	0.9	97
171	Incidence of Ischemic Colitis and Serious Complications of Constipation Among Patients Using Alosetron: Systematic Review of Clinical Trials and Post-Marketing Surveillance Data. American Journal of Gastroenterology, 2006, 101, 1069-1079.	0.2	151
172	Impact of irritable bowel syndrome on patients?? lives: development and psychometric documentation of a disease-specific measure for use in clinical trials. European Journal of Gastroenterology and Hepatology, 2005, 17, 411-420.	0.8	52
173	Diagnosis and treatment of irritable bowel syndrome: State of the art. Current Gastroenterology Reports, 2005, 7, 249-256.	1.1	30
174	New insights into the pathophysiology of irritable bowel syndrome: Implications for future treatments. Current Gastroenterology Reports, 2005, 7, 272-279.	1.1	44
175	A randomised controlled trial assessing the efficacy and safety of repeated tegaserod therapy in women with irritable bowel syndrome with constipation. Gut, 2005, 54, 1707-1713.	6.1	150
176	Sex specific alterations in autonomic function among patients with irritable bowel syndrome. Gut, 2005, 54, 1396-1401.	6.1	127
177	A Comparison of Visceral and Somatic Pain Processing in the Human Brainstem Using Functional Magnetic Resonance Imaging. Journal of Neuroscience, 2005, 25, 7333-7341.	1.7	234
178	Brain Responses to Visceral and Somatic Stimuli in Irritable Bowel Syndrome: a Central Nervous System Disorder?. Gastroenterology Clinics of North America, 2005, 34, 271-279.	1.0	58
179	Characterization of the Alternating Bowel Habit Subtype in Patients with Irritable Bowel Syndrome. American Journal of Gastroenterology, 2005, 100, 896-904.	0.2	113
180	Differences in brain responses to visceral pain between patients with irritable bowel syndrome and ulcerative colitis. Pain, 2005, 115, 398-409.	2.0	251

#	Article	IF	CITATIONS
181	Cortical processing of visceral and somatic stimulation: Differentiating pain intensity from unpleasantness. Neuroscience, 2005, 133, 533-542.	1.1	120
182	ls a negative colonoscopy associated with reassurance or improved health-related quality of life in irritable bowel syndrome?. Gastrointestinal Endoscopy, 2005, 62, 892-899.	0.5	74
183	A Dose-Ranging, Phase II Study of the Efficacy and Safety of Alosetron in Men with Diarrhea-Predominant IBS. American Journal of Gastroenterology, 2005, 100, 115-123.	0.2	125
184	Review article: epidemiology and quality of life in functional gastrointestinal disorders. Alimentary Pharmacology and Therapeutics, 2004, 20, 31-39.	1.9	288
185	Sex-based differences in gastrointestinal pain. European Journal of Pain, 2004, 8, 451-463.	1.4	93
186	Racial Differences in the Impact of Irritable Bowel Syndrome on Health-Related Quality of Life. Journal of Clinical Gastroenterology, 2004, 38, 782-789.	1.1	39
187	The Effect of Life Stress on Symptoms of Heartburn. Psychosomatic Medicine, 2004, 66, 426-434.	1.3	127
188	Clinical Determinants of Health-Related Quality of Life in Patients With Irritable Bowel Syndrome. Archives of Internal Medicine, 2004, 164, 1773.	4.3	158
189	Gender-Related Differences in Functional Bowel Disorders. , 2004, , 438-445.		1
190	Brain-gut interactions: implications for newer therapy. The European Journal of Surgery, 2003, 164, 50-55.	1.0	9
191	Clinical determinants of health-related quality of life in irritable bowel syndrome. Gastroenterology, 2003, 124, A398.	0.6	2
192	Sex-related differences in IBS patients: central processing of visceral stimuli. Gastroenterology, 2003, 124, 1738-1747.	0.6	264
193	Impact of Sex and Gender on Irritable Bowel Syndrome. Biological Research for Nursing, 2003, 5, 56-65.	1.0	85
194	Prevalence of irritable bowel syndrome among university students. Journal of Psychosomatic Research, 2003, 55, 501-505.	1.2	137
195	Brain Responses To Visceral and Somatic Stimuli in Patients With Irritable Bowel Syndrome With and Without Fibromyalgia. American Journal of Gastroenterology, 2003, 98, 1354-1361.	0.2	106
196	Irritable bowel syndrome patients show enhanced modulation of visceral perception by auditory stress. American Journal of Gastroenterology, 2003, 98, 135-143.	0.2	192
197	Utility of the Rome I and Rome II criteria for irritable bowel syndrome in U.S. women. American Journal of Gastroenterology, 2002, 97, 2803-2811.	0.2	86
198	Is There a Difference Between Abdominal Pain and Discomfort in Moderate to Severe IBS Patients?. American Journal of Gastroenterology, 2002, 97, 3131-3138.	0.2	26

#	Article	IF	CITATIONS
199	Enhanced preattentive central nervous system reactivity in irritable bowel syndrome. American Journal of Gastroenterology, 2002, 97, 2791-2797.	0.2	54
200	Condition-specific deactivation of brain regions by 5-HT3 receptor antagonist Alosetron. Gastroenterology, 2002, 123, 969-977.	0.6	128
201	Gender differences in irritable bowel syndrome. Gastroenterology, 2002, 123, 1686-1701.	0.6	268
202	Irritable bowel syndrome. Current Treatment Options in Gastroenterology, 2002, 5, 267-278.	0.3	7
203	Evolving pathophysiological model of functional gastrointestinal disorders: implications for treatment. The European Journal of Surgery Supplement: = Acta Chirurgica Supplement, 2002, , 3-9.	0.2	7
204	The effect of the 5-HT3 receptor antagonist alosetron on regional brain activation in IBS patients is not dependent on activation of nociceptive visceral afferents: A H215O PET study. Gastroenterology, 2001, 120, A67.	0.6	2
205	Comment on â€~Differences in somatic perception in female patients with irritable bowel syndrome with and without fibromyalgia' L. Chang et al., PAIN 84 (2000) 297–307. Pain, 2001, 91, 404-405.	2.0	0
206	The role of gender and bowel habit predominance on visceral perception in IBS. Gastroenterology, 2001, 120, A755.	0.6	3
207	Sensation of bloating and visible abdominal distension in patients with irritable bowel syndrome. American Journal of Gastroenterology, 2001, 96, 3341-3347.	0.2	163
208	V. Stress and irritable bowel syndrome. American Journal of Physiology - Renal Physiology, 2001, 280, G519-G524.	1.6	362
209	Cerebral Activation in Patients With Irritable Bowel Syndrome and Control Subjects During Rectosigmoid Stimulation. Psychosomatic Medicine, 2001, 63, 365-375.	1.3	291
210	Gender-related differences in IBS symptoms. American Journal of Gastroenterology, 2001, 96, 2184-2193.	0.2	190
211	Basic Pathophysiologic Mechanisms in Irritable Bowel Syndrome. Digestive Diseases, 2001, 19, 212-218.	0.8	69
212	Preoperative Versus Postoperative Endoscopic Retrograde Cholangiopancreatography in Mild to Moderate Gallstone Pancreatitis. Annals of Surgery, 2000, 231, 82.	2.1	121
213	Gender differences in regional brain response to visceral pressure in IBS patients. European Journal of Pain, 2000, 4, 157-172.	1.4	157
214	Correlation of symptom criteria with perception thresholds during rectosigmoid distension in irritable bowel syndrome patients. American Journal of Gastroenterology, 2000, 95, 152-156.	0.2	71
215	Differences in somatic perception in female patients with irritable bowel syndrome with and without fibromyalgia. Pain, 2000, 84, 297-307.	2.0	174
216	Towards an integrative model of irritable bowel syndrome. Progress in Brain Research, 2000, 122, 413-423.	0.9	22

#	Article	IF	CITATIONS
217	A double blind parallel group pilot study of the effects of CJ-11,974 and placebo on perceptual and emotional responses to rectosigmoid distension in IBS patients. Gastroenterology, 2000, 118, A846.	0.6	25
218	Differences in rectal mechanoelastic properties according to predominant bowel habit in IBS patients. Gastroenterology, 2000, 118, A667.	0.6	2
219	Ratings of sigmoid but not rectal distensions correlate with IBS symptom severity. Gastroenterology, 2000, 118, A445.	0.6	2
220	Evidence for selective effect of the 5HT3 antagonist alosetron on amygdala and hippocampal activation in IBS patients. Gastroenterology, 2000, 118, A81.	0.6	2
221	Gender differences in autonomic activity in IBS. Gastroenterology, 2000, 118, A137.	0.6	1
222	Evidence for decreased activation of central fear circuits by expected aversive visceral stimuli in IBS patients. Gastroenterology, 2000, 118, A137.	0.6	7
223	Approaches to the Modulation of Abdominal Pain. Canadian Journal of Gastroenterology & Hepatology, 1999, 13, 66A-70A.	1.8	6
224	Symptom Differences in Moderate to Severe Ibs Patients Based on Predominant Bowel Habit. American Journal of Gastroenterology, 1999, 94, 2929-2935.	0.2	109
225	Diagnostic approach to the patient with irritable bowel syndrome. American Journal of Medicine, 1999, 107, 20-26.	0.6	29
226	The Association of Functional Gastrointestinal Disorders and Fibromyalgia. The European Journal of Surgery, 1998, 164, 32-36.	1.0	41
227	Gallstone Pancreatitis: A Prospective Study on the Incidence of Cholangitis and Clinical Predictors of Retained Common Bile Duct Stones. American Journal of Gastroenterology, 1998, 93, 527-531.	0.2	89
228	Does mind-body medicine have a role in gastroenterology?. Current Opinion in Gastroenterology, 1997, 13, 1-4.	1.0	11
229	Early computed tomography is rarely necessary in gallstone pancreatitis. American Surgeon, 1997, 63, 904-7.	0.4	9
230	Admission factors can predict the need for ICU monitoring in gallstone pancreatitis. American Surgeon, 1996, 62, 815-9.	0.4	15
231	Clostridial bacteremia: implications for the surgeon. American Surgeon, 1991, 57, 388-93.	0.4	9